India's turnaround specialist Sun snaps Ranbaxy in $4bn deal
This article was originally published in Scrip
Executive Summary
Six years after Japan's Daiichi Sankyo acquired Ranbaxy Laboratories in June 2008, it has handed over the reins of company to India's distressed asset turnaround specialist and Sun Pharma founder, Dilip Shanghvi.
You may also be interested in...
Singh Brothers Asked To Pay Up $550m Arbitral Award To Daiichi
An Indian court has ruled that tycoons Malvinder and Shivinder Singh must pay Daiichi Sankyo $550m in damages originally awarded by a Singapore arbitration panel over the Japanese drugmaker’s ill-fated purchase of generic giant Ranbaxy.
Daiichi Arbitration Case Bares Trail Of Deception At Ranbaxy
Incriminating details in an arbitration order against the former Ranbaxy top brass led by the Singh brothers has put the spotlight back on allegations of misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against the Indian company at the time of its takeover by Daiichi Sankyo. The Singh brothers, who have challenged the award, though, have cried foul, questioning the timing of the apparent leak of the "confidential" award ahead of a court hearing.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.